Latest Breaking News On - Mary ann chang - Page 2 : comparemela.com

FDA Grants Orphan Drug Designation to Temferon for Treatment of Glioblastoma Multiforme

02.03.2023 - MILAN and NEW YORK, March 02, 2023 (GLOBE NEWSWIRE) - Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments .

Genenta Update at SITC22 Indicates Potential for Anti-Tumor Immune System Reset after Temferon™ Treatment in Glioblastoma Patients

Ultimovacs Announces Positive Three-Year Results of 71%

Malignant melanoma patients treated with immunotherapy combination UV1 and pembrolizumab in phase I clinical trialConsistently high overall survival (OS).

Ultimovacs Announces Plenary Oral Presentation of Phase I Melanoma Trial Results at the 19th International Congress of the Society for Melanoma Research (SMR)

Ultimovacs Announces Publication of Phase I Melanoma Trial Data in Journal of Translational Medicine